AzTrials
AzTrials

Condition

Attention Deficit Hyperactivity Disorder Clinical Trials

Studies of attention deficit hyperactivity disorder, matched by condition name and medical subject headings. Start with those open to enrolment.

1,798 registered studies

In numbers

Open to volunteers
240
Active
276
With results posted
368
All registered
1,798

Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.

Open to volunteers

All 240
  • Attention Deficit Hyperactivity Disorder (ADHD)

    A Long-term Trial of EB-1020 in Adult Patients With ADHD

    • Recruiting
    • Age: 18 to 55 years
    • Phase 3
    • Pill or oral medicine

    The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in patients who have completed the double-blind trial (405-102-00112) conducted in Japan

    Trial name
    NCT06926829
    Testing
    EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg
    Where
    Japan
    Volunteers
    180 people
    Sponsor
    Otsuka Pharmaceutical Co., Ltd.
    Can I take part? NCT06926829
  • Attention Deficit Hyperactivity Disorder (ADHD)

    Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients

    • Recruiting
    • Age: 18 to 55 years
    • Phase 2/3
    • Pill or oral medicine

    The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in adult ADHD patients.

    Trial name
    NCT06931080
    Testing
    EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg
    Where
    Japan
    Volunteers
    630 people
    Sponsor
    Otsuka Pharmaceutical Co., Ltd.
    Can I take part? NCT06931080
  • Irritability, Disruptive Mood Dysregulation Disorder

    Psychotherapy for Irritability in Youth: Comparing Active Treatment to Nonactive Psychoeducation Supportive Psychotherapy

    • Recruiting
    • Age: 8 to 17 years
    • Observational study
    • Lifestyle or therapy programme

    Background: Irritability is defined as proneness to anger that may impair a person's ability to function. It is a common reason for why some children need mental health care.

    Conditions
    Irritability, Disruptive Mood Dysregulation Disorder, Oppositional Defiant Disorder, Attention Deficit Hyperactivity Disorder
    Trial name
    NCT07640802
    Testing
    Psychotherapy
    Where
    United States
    Volunteers
    410 people
    Sponsor
    National Institute of Mental Health (NIMH)
    Can I take part? NCT07640802
  • Disruptive Behavior Disorders, Conduct Disorder

    Augmenting Parent Management Training for Child Temper Outbursts Using a Digital Tool

    • Recruiting
    • Age: 8 to 13 years
    • Observational study
    • Lifestyle or therapy programme

    Background: Pediatric disruptive behavior disorders (DBDs) are characterized by severe irritability, anger, and temper outbursts. The primary way to treat children with DBDs is parent management training (PMT).

    Conditions
    Disruptive Behavior Disorders, Conduct Disorder, Oppositional Defiant Disorder, Attention-deficit/Hyperactivity Disorder
    Trial name
    NCT07764536
    Testing
    Psychotherapy
    Where
    United States
    Volunteers
    200 people
    Sponsor
    National Institute of Mental Health (NIMH)
    Can I take part? NCT07764536
  • ADHD, Autism Spectrum Disorder

    AWARE: Management of ADHD in Autism Spectrum Disorder

    • Recruiting
    • Age: 4 to 17 years
    • Phase 4
    • Pill or oral medicine

    This study is a pragmatic clinical trial examining the comparative effectiveness of two stimulant medications (methylphenidate and amphetamine) in the treatment of ADHD in children and adolescents with autism.

    Trial name
    NCT05916339
    Testing
    Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication, Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
    Where
    13 sites in United States, Canada
    Volunteers
    500 people
    Sponsor
    Daniel Coury
    Can I take part? NCT05916339
  • Attention Deficit Disorder With Hyperactivity (ADHD), Autism Spectrum Disorder (ASD)

    External Trigeminal Nerve Stimulation for Children With ASD + ADHD to Reduce Elevated Symptoms

    • Recruiting
    • Age: 7 to 14 years
    • Medical device

    The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD).

    Trial name
    eTNS CARES (NCT07214545)
    Testing
    Trigeminal Nerve Stimulation
    Where
    United States
    Volunteers
    60 people
    Sponsor
    University of California, San Francisco
    Can I take part? eTNS CARES
  • Attention-Deficit/Hyperactivity Disorder (ADHD)

    Developing Virtual Reality Programs to Address Social Skills Deficits in Youth With ADHD

    • Not yet recruiting
    • Age: 10 to 15 years
    • Medical device

    Researchers at OpenMindXR, in collaboration with Indiana University, are conducting a paid research study evaluating an innovative virtual reality (VR)-based intervention designed to support social and emotional skill development…

    Trial name
    NCT07882823
    Testing
    VIP Suite
    Volunteers
    48 people
    Sponsor
    Indiana University
    Can I take part? NCT07882823
  • ADHD

    Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

    • Recruiting
    • Age: 6 to 11 years
    • Phase 3
    • Pill or oral medicine

    This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in children aged 6 to <12 years with ADHD.

    Trial name
    NCT07717879
    Testing
    Solriamfetol Dose A, Solriamfetol Dose B
    Where
    30 sites in United States
    Volunteers
    468 people
    Sponsor
    Axsome Therapeutics, Inc.
    Can I take part? NCT07717879
  • ADHD

    Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

    • Recruiting
    • Age: 12 to 17 years
    • Phase 3
    • Pill or oral medicine

    This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in adolescents aged 12 to <18 years with ADHD.

    Trial name
    NCT07717892
    Testing
    Solriamfetol Dose A, Solriamfetol Dose B
    Where
    28 sites in United States
    Volunteers
    468 people
    Sponsor
    Axsome Therapeutics, Inc.
    Can I take part? NCT07717892
  • ADHD

    An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD

    • Enrolling by invitation
    • Age: 6 to 18 years
    • Phase 3
    • Pill or oral medicine

    This study is a Phase 3, multi-center, open-label trial to evaluate the long-term safety of solriamfetol in children and adolescents with ADHD.

    Trial name
    NCT07773883
    Testing
    Solriamfetol
    Where
    7 sites in United States
    Volunteers
    300 people
    Sponsor
    Axsome Therapeutics, Inc.
    Can I take part? NCT07773883

Completed, with results posted

All –
  • ADHD, Parenting

    Treating Parents With ADHD and Their Young Children Via Telehealth: A Hybrid Type I Effectiveness-Implementation Trial

    • Completed
    • Age: 3 to 65 years
    • Phase 3
    • Lifestyle or therapy programme
    • Results posted

    This study will compare the effectiveness of combined parental stimulant medication and behavioral parent training (BPT) versus BPT alone on child ADHD-related impairment (primary outcome), child ADHD and externalizing symptoms…

    Trial name
    TPAC (NCT04240756)
    Testing
    Behavioral Parent Training, Extended release mixed amphetamine salts (MAS)
    Where
    United States
    Volunteers
    269 people
    Sponsor
    University of Maryland, College Park
    Can I take part? TPAC
  • Virtual Reality, Social Interaction

    Social Virtual-reality on Enhancing Social Interaction Skills in Children With Attention-deficit/Hyperactivity Disorder

    • Completed
    • Age: 6 to 12 years
    • Lifestyle or therapy programme
    • Results posted

    The study targets children with diagnosed ADHD and aims to (1) develop a social virtual reality-based intervention, (2) investigate its effects on improving the social skills and executive functioning of inhibitions, emotional…

    Conditions
    Virtual Reality, Social Interaction, Attention-deficit/Hyperactivity Disorder
    Trial name
    NCT05778526
    Testing
    Virtual reality, Traditional social skills training
    Where
    Hong Kong
    Volunteers
    90 people, healthy volunteers welcome
    Sponsor
    The Hong Kong Polytechnic University
    Can I take part? NCT05778526
  • ADHD, ADHD - Combined Type

    Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.

    • Completed
    • Age: 18 to 55 years
    • Phase 3
    • Pill or oral medicine
    • Results posted

    The goal of this clinical trial is to evaluate the efficacy and safety of CTx-1301 in adults with ADHD in a laboratory classroom setting.

    Conditions
    ADHD, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention Deficit Hyperactivity Disorder
    Trial name
    NCT05631626
    Testing
    CTx-1301 - Dexmethylphenidate 25mg, CTx-1301 - Dexmethylphenidate 37.5mg, CTx-1301 - Dexmethylphenidate 50mg
    Where
    United States
    Volunteers
    26 people
    Sponsor
    Cingulate Therapeutics
  • ADHD

    Improving the Outcomes of Adolescents With ADHD Via a Pre-visit Question Prompt List/Video Intervention

    • Completed
    • Age: 11 to 17 years
    • Lifestyle or therapy programme
    • Results posted

    The investigators propose to conduct a pilot randomized controlled feasibility trial to evaluate the feasibility and effectiveness of a pre-visit intervention to improve communication about attention deficit hyperactivity…

    Trial name
    NCT05835362
    Testing
    Question Prompt List, Video Only
    Where
    United States
    Volunteers
    252 people
    Sponsor
    University of North Carolina, Chapel Hill
  • Neurofibromatosis 1

    Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1

    • Completed
    • Age: 8 to 16 years
    • Phase 2
    • Results posted

    Children with neurofibromatosis type 1 (NF1) commonly suffer from the effects of cognitive, behavioral, and motor impairments. At present, there is no specific treatment for this NF1 complication.

    Trial name
    DoDNAC (NCT04481048)
    Testing
    N-Acetyl cysteine
    Where
    United States
    Volunteers
    25 people, healthy volunteers welcome
    Sponsor
    Children's Hospital Medical Center, Cincinnati
    Can I take part? DoDNAC

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in